Ribrecabtagene autoleucel (Aurigene Oncology)

N/A

Report date: 2025/01/21 17:01:34

Base Information

Drug NameRibrecabtagene autoleucel (Aurigene Oncology)
Drug Alias NameDRL-1801
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAurigene Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAurigene Oncology Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A